Capricor Therapeutics Inc
Veridion Score
Composite trend over time
Why is CAPR moving today?
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for CAPR.
CAPR insider activity
Capricor Therapeutics Inc
3 insiders bought in the last 90 days
Net selling: -$6.0M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-24 | 2026-06-24 | Bergmann Anthony | Insider | sell | $30.00 | 400 | 11,223 | $12K | SEC Form 4 |
| 2026-06-24 | 2026-06-24 | Bergmann Anthony | Insider | buy | $3.18 | 400 | 11,623 | $1K | SEC Form 4 |
| 2026-06-24 | 2026-06-24 | Krasney Karen | Insider | sell | $30.00 | 400 | 30,547 | $12K | SEC Form 4 |
| 2026-06-24 | 2026-06-24 | Krasney Karen | Insider | buy | $3.18 | 400 | 30,947 | $1K | SEC Form 4 |
| 2026-06-24 | 2026-06-22 | Bergmann Anthony | Insider | sell | $30.00 | 500 | 11,223 | $15K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 23 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moCAPR contract awards, year to date.
Public federal awards linked to this ticker.
CAPR lobbying filings, year to date.
Registered lobbying filings matched to Capricor Therapeutics Inc.